NASDAQ: SLN - Silence Therapeutics plc

Rentabilité sur six mois: -18.71%
Secteur: Healthcare

Calendrier des promotions Silence Therapeutics plc

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

Plus de détails
The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 0.000244
EBITDA -0.0222
Число акций ао 0.03709 млрд
P/S 81.28
P/BV 49.16
EV/EBITDA 0.5952
Цена ао 19.27
ISIN US82686Q1013
Сайт https://www.silence-therapeutics.com
Валюта usd
IPO date 2020-09-08
Sector Health Care
Industry Biotechnology
Валюта отчета gbp
Changement de prix par jour: 0% (18.29)
Changement de prix par semaine: -5.23% (19.3)
Changement de prix par mois: +0.3291% (18.23)
Changement de prix sur 3 mois: -11.51% (20.67)
Changement de prix sur six mois: -18.71% (22.5)
Changement de prix par an: +147.83% (7.38)
Evolution du prix sur 3 ans: -13.24% (21.08)
Evolution des prix depuis le début de l'année: +51.53% (12.07)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 19.51 1
P/BV 29.03 1
P/E 0 0
EV/EBITDA -9.26 0
Total: 3.13

Efficacité

Nom Signification Grade
ROA, % -46.12 0
ROE, % -253.77 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0057 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 10299.59 10
Rentabilité Ebitda, % 114.44 10
Rentabilité EPS, % 241.07 10
Total: 8
Plus de détails

Établissements Volume Partager, %
Lombard Odier Asset Management (USA) Corp 3879173 12.96
Lombard Odier Asset Management (Europe) Ltd 3612877 12.07
Artal Group S.A. 3000000 10.02
Tcg Crossover Management, Llc 2104875 7.03
Deep Track Capital, LP 1951580 6.52
BVF Inc. 1508416 5.04
Aquilo Capital Management, LLC 1043284 3.49
Frazier Life Sciences Management, L.P. 881173 2.94
Vivo Capital, LLC 510204 1.7
Logos Global Management LP 400000 1.34

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Virtus LifeSci Biotech Clinical Trials ETF 0.73377 77.329244365683 0.33
SPDR Portfolio MSCI Global Stock Market ETF 0 29.55850326668 2.19607



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Craig A. Tooman M.B.A. President, CEO & Executive Director 1.49M 1965 (59 années)
Ms. Rhonda L. Hellums Executive VP, CFO & Secretary 907.23k 1972 (52 année)
Dr. Steven J. Romano M.D. Executive VP and Chief Research & Development Officer 662.65k 1959 (65 années)
Dr. Marie Wikstrom Lindholm Ph.D. Chief Scientific Officer N/A
Ms. Gem Gokmen Hopkins Head of IR & Corporate Communications N/A
Dr. Barbara A. Ruskin J.D., Ph.D. Senior VP and Chief Intellectual Property & Innovation Officer N/A 1960 (64 année)
Dr. Eric Floyd M.B.A., M.S., Ph.D. Senior Vice President of Regulatory Affairs & Quality Assurance N/A 1963 (61 année)
Mr. J.P. Gabriel Chief Technical Operations Officer N/A
Mr. Curtis Rambaran M.D. Chief Medical Officer N/A
Ms. Gianine Esposito Chief Human Resources Officer

Adresse: United Kingdom, London, 72 Hammersmith Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.silence-therapeutics.com